Equillium Buys Inflammatory Bowel Disease Player In All-Stock Deal
Equillium Inc (NASDAQ:EQ) has agreed to acquire Metacrine Inc (NASDAQ:MTCR) in an all-stock transaction. The transaction is anticipated to add $33 million…
ACOGF: Bioequivalence Complete
By John Vandermosten, CFA
OTC:ACOGF
READ THE FULL ACOGF RESEARCH REPORT
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
ONE WORLD LITHIUM INC. Announces Private Placement & Stock Option Grants
Not for Distribution to United States Newswire Services or for Dissemination in The United States VANCOUVER, BC –…
Jake Paul Launches Betr App, Potentially Making Him (And You) Richer
Jake Paul, former Walt Disney actor and current YouTube star-turned-boxer, has launched micro-betting sports platform Betr alongside Joey Levy, founder of Simplebet, after rasing $30 million in a Series A funding round with investments from rapper Travis Scott andpro football players Ezekiel Elli
Eledon Shares Climb After Securing FDA Nod For Mid-Stage Kidney Disease Study
Eledon Pharmaceuticals (NASDAQ: ELDN) received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).
Dow Tumbles Over 200 Points; ChannelAdvisor Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping around 3%, and the S&P 500 down around 3.3%.
Unions Make Inroads In Cannabis Industry With Latest Dispensary Joining The Ranks
Workers at the Trulieve (OTCQX: TCNNF) North Shore medical cannabis dispensary have voted to join Local 1776.
This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout
Raymond James downgraded PolyPid Ltd (NASDAQ:PYPD) from Strong Buy to Outperform post SHIELD I Phase 3 results that, despite consistency and evidence of…
Athira Outlines Possible Comeback For Alzheimer’s Candidate
Athira Pharma Inc (NASDAQ:ATHA) announced an update to its plans for the ongoing LIFT-AD trial of fosgonimeton (ATH-1017) for mild-to-moderate Alzheimer’s…